NASDAQ:KROS

Analysts review Keros Therapeutics Inc’s rating
Roman Campbell
Keros Therapeutics Inc’s recently made public that its 10% Owner Pontifax Management 4 G.P. (20 unloaded Company’s shares for reported ...

Keros Therapeutics Inc’s recently made public that its 10% Owner Pontifax Management 4 G.P. (20 unloaded Company’s shares for reported ...